Cognitive Diagnostics Market - Strategic Insights and Forecasts (2025-2030)

The Cognitive Diagnostics market is forecast to grow at a CAGR of 7.8%, reaching USD 214.60 billion in 2031 from USD 147.70 billion in 2026.

The cognitive diagnostics market is related to the field of medical technology that involves the assessment and diagnosis of cognitive disorders. The cognitive diagnostics market is driven by factors such as the increasing geriatric population, growing chronic disease ailments, and rising awareness about cognitive decline. As per the research, certain cognitive functions, including memory, executive functions, processing speed, and reasoning, begin to decline as early as the thirties. Furthermore, studies suggest that mild cognitive impairment affects 10-20% of adults over 65, with the potential to evolve into more severe cognitive issues.

The introduction of innovative products and new metrics related to cognitive functions is further bolstering the market. Muse by Interaxon announced the launch of a new cognitive performance metric, Alpha Peak, in September 2024. As the first in a suite of advanced brain health metrics, Alpha Peak empowers users to enhance cognitive performance through personalized, actionable insights with an easy-to-understand score, paving the way for enhanced mental fitness. The users can monitor lifestyle factors such as diet, exercise, and sleep, which can directly correlate changes with their Alpha Peak score, and receive personalized prompts to optimize their habits accordingly.

• The major development had been taking place through strategic partnerships and investments. In August 2024, Firefly Neuroscience, Inc. announced that it formed a strategic partnership with the Neurology Consultants of Dallas. (NCD) This would help to enhance early detection efforts and disease management for patients suffering from cognitive decline. NCD would incorporate Firefly’s Brain Network Analytics technology into its patient workflow and conduct clinical studies. Firefly Neuroscience, Inc. is an artificial intelligence technology company developing innovative neuroscientific solutions to improve brain health outcomes for patients with mental illnesses and neurological disorders.

• Further, C?N Diagnostics, LLC, and Eisai Inc. announced that Eisai invested up to 15 million USD in C?N in March 2024. The investment reflects that companies shared a desire to scale up and provide broad access to their Precivity tests. Precision tests are innovative blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers to determine Alzheimer’s disease pathology and aid in medical management and treatment decisions.

Cognitive Diagnostics Market Drivers:

• Rising population, geriatric population

The growing elderly population worldwide is the leading cause of the demand for cognitive diagnostics and treatments. The aging population has an immense effect on the healthcare sector. According to the WHO^[1], by 2030, 1 in 6 people will be 60 years or over. By then, the share of the population aged 60 years will be 1.4 billion.

By 2050, the world’s population of people aged 60 years and older will be 2.1 billion. The cognitive diagnostics market will benefit from this increasing elderly population. A disease like Alzheimer's is the most common form of dementia among older adults. This is an irreversible degeneration of the brain that causes disruptions in memory, cognition, personality, and other functions. Further, Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer's disease, which affects up to two million Americans, mostly aged 60 and older. These diseases need proper diagnostics and treatments, hence the cognitive diagnostics market will be fueled by the growing grey population.

• Growing chronic disease ailments among a large population

Chronic diseases tend to be of long duration and are the result of a combination of genetic, physiological, environmental, and behavioral factors. The major types of chronic diseases are heart attacks, stroke, cancer, diabetes, asthma, etc. Most of these diseases account for 80% of all premature deaths. The increasing number of chronic diseases and ailments can cause long-term and short-term cognitive impairment. The proper cognitive diagnostics are needed to understand the complications of these cognitive impairments.

Cognitive Diagnostics Market Geographical Outlook:

By geography, the cognitive diagnostics market is segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The major economies like China, Japan, India, and South Korea dominate the Asia-Pacific region. Some of the fastest-growing emerging economies are from this region such as ASEAN countries.

The Asia Pacific region is expected to see notable growth in the healthcare industry, as the population of the elderly grows and growing concern for chronic ailments. According to the Asian Development Bank, by 2050, one in four people in Asia and the Pacific will be over 60 years old. The population aged over 60 in the region will triple between 2010 and 2050, reaching close to 1.3 billion people. In some countries, this transition will happen very rapidly, such as China, Japan, South Korea, and Vietnam. Further, growing research on the fields of depression, insomnia, and PTSD will increase the demand for devices and drugs to enhance the quality of life for those affected in the region.

Cognitive Diagnostics Market Key Developments

The market leaders for the cognitive diagnostics market are Cognivue, Inc., Cambridge Cognition Ltd., Diadem srl, CN Diagnostics, Cogstate Ltd., Viz.ai, Mind Maze, Neurocare Group AG, Anderson Diagnostics & Labs., Altoida AG, BrainScope Company Inc., Neurotrack Technologies Inc., BrainCheck, and Cyclops MedTech Pvt Ltd. The key players in the market implement growth strategies such as product launches, mergers, acquisitions, etc., to gain a competitive advantage over their competitors. For Instance,

February 2026: BrainCheck Inc. reported the expansion of its FDA-cleared digital cognitive assessment platform across more than 150 additional healthcare practices in 2025, significantly scaling clinical adoption for cognitive screening and monitoring.

December 2025: QHSLab Inc. announced the launch of Q-Cog™, a cloud-based cognitive assessment platform designed to help primary care providers identify mild cognitive impairment and dementia risks earlier using integrated digital screening tools.

October 2025: Roche Diagnostics, in collaboration with Eli Lilly, received U.S. FDA clearance for the Elecsys blood test to aid early Alzheimer’s disease assessment by detecting the pTau181 biomarker in patients with cognitive decline symptoms.

May 2025: Cognivue, Inc. announced the launch of the Cognivue Amyloid Risk Measure (CARM) feature on the Cognivue Clarity device, enabling clinicians to estimate amyloid biomarker risk and improve early Alzheimer’s disease detection.

Cognitive Diagnostics Market Scope: